Evercore ISI Group Downgrades Guardant Health to In-Line, Raises Price Target to $105

Benzinga · 6d ago
Evercore ISI Group analyst Daniel Markowitz downgrades Guardant Health (NASDAQ:GH) from Outperform to In-Line and raises the price target from $90 to $105.